Aurora Spine Stock Price, News & Analysis

Aurora Spine Corporation (OTCQB: ASAPF) will release its financial results for Q4 and FY 2022 on May 1, 2023. The conference call is scheduled for 12:00 p.m. ET to discuss these results. Interested participants can join the call via a toll-free number or through a live webcast. The replay of the conference will be accessible for a week post-call. The company specializes in innovative spinal implant technologies aimed at enhancing surgical outcomes.

Aurora emphasizes transparency, indicating that forward-looking statements may pose risks and uncertainties. Readers are advised not to overly rely on projections made in the release.

Aurora Spine Corporation announced its presentation at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 3:00 PM PST. Trent Northcutt, President and CEO, will lead the presentation and answer questions afterward. The event aims to engage with investors, sharing the company's recent achievements and growth potential. The presentation can be accessed via a live webcast. For those interested in one-on-one meetings, registration is required at the event's website. Aurora Spine specializes in innovative spinal implant technologies, focusing on minimally invasive solutions to enhance surgical outcomes. The company's ticker symbol is ASAPF.

Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) has announced its participation in the 2023 AANS Annual Scientific Meeting from April 21-24, 2023, at the Los Angeles Convention Center, Booth #1011. The Company will showcase its innovative spinal surgery solutions, including the DEXA-C™ cervical cage, designed for anterior cervical discectomy with fusion (ACDF) procedures. DEXA-C uses patented DEXA Technology™ to align with patients' bone densities. Additionally, Dr. Sebastian Koga will present on April 23rd, discussing the advantages of 3D printed fusion devices. Aurora will also feature its SiLO TFX™ SI Fusion System for sacroiliac joint fusion and ZIP products for minimally invasive procedures. CEO Trent Northcutt expressed enthusiasm for engaging with leading neurosurgeons at the event.

Aurora Spine Corporation (OTCQB: ASAPF) announced the successful initial surgeries of its FDA-approved SiLO TFX™ MIS Sacroiliac Joint Fixation Device, with over a dozen patients receiving the implant. The SiLO TFX is designed for sacroiliac joint fusion, targeting conditions like joint disruptions and degenerative sacroiliitis. With a significant market potential, 30 million Americans suffer from lower back pain, with 4.7 million experiencing SI joint pain. The device simplifies the implantation process, aligning with existing non-surgical treatment methods. CEO Trent Northcutt expressed optimism regarding the device's capability to enhance surgical outcomes, signaling a forthcoming full market launch by mid-year. Surgeons have praised the device's seamless technique and potential for superior results.

Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) announced that its DEXA Technology will be showcased at the AANS Annual Scientific Meeting from April 21-24, 2023. Dr. Sebastian Koga will present findings on the DEXA-C device, demonstrating its 43% lower risk of subsidence compared to standard PEEK cages. Subsidence is a complication in spinal surgeries where vertebral discs sink around implants, which can lead to instability. Dr. Koga emphasized that DEXA-C's design, which matches patient bone density, enhances performance in older patients with low bone density. Aurora's President, Trent Northcutt, expressed excitement about the device's strength and superior performance during the presentation.

Aurora Spine has announced the approval for a multicenter study of its DEXA-C™ Cervical Interbody System, aimed at improving spinal surgery outcomes. Seven sites have been selected, three are pending approval, with patient enrollment anticipated soon. The clinical trial will involve 80 subjects, assessing the system's effectiveness in anterior cervical discectomy and fusion procedures. Aurora's patented DEXA™ technology targets varying bone densities to enhance fusion success. Key outcomes will be monitored at multiple post-surgery intervals, focusing on fusion assessment and patient-reported results.

Aurora Spine Corporation (OTCQB: ASAPF) announced IRB approval for a multicenter study of its DEXA-C Cervical Interbody System, aimed at anterior cervical interbody fusion in patients with degenerative disc disease. This system utilizes Aurora's patented DEXA technology, designed to match implants with a patient’s bone density. The study will involve 10 sites across the U.S. with data from at least 80 subjects. Initial beta-testing responses have been positive, with researchers optimistic about improved surgical outcomes. The study will evaluate fusion success and subsidence metrics at various follow-up intervals.

Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) will present at the Planet MicroCap Showcase: VIRTUAL 2022 on December 7, 2022, at 10:00 AM EST. President and CEO Trent Northcutt and CFO Chad Clouse will lead the session, followed by a Q&A. Attendees can register for 1on1 meetings or view the presentation via the conference's online platform. Aurora Spine focuses on innovative, minimally invasive spinal devices aimed at improving surgical outcomes. For more information, visit aurora-spine.com.

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will release its third-quarter financial results for the period ended September 30, 2022, on November 21, 2022. Following the release, management will hold a conference call at 11:00 a.m. ET to discuss the results, which can be accessed via phone or a live webcast. The replay of this call will be available until November 28, 2022. Aurora Spine focuses on innovative, minimally invasive spinal implant technologies aimed at improving surgical outcomes.